博纳文图拉等人对(2R,6R)-羟基诺氯胺酮抗抑郁样作用行为测试的评论 - Suppr

Suppr

超能文献

Comments to behavioral tests for antidepressant-like actions of (2R,6R)-hydroxynorketamine by Bonaventura et al.

作者信息

Chang Lijia, Hashimoto Kenji

机构信息

Division of Clinical Neuroscience, Chiba University Center for Forensic Mental Health, Chiba, 260-8670, Japan.

出版信息

Mol Psychiatry. 2024 Jan;29(1):3-4. doi: 10.1038/s41380-022-01766-6. Epub 2022 Sep 13.

DOI:10.1038/s41380-022-01766-6

PMID:36100667

Abstract

摘要

相似文献

Comments to behavioral tests for antidepressant-like actions of (2R,6R)-hydroxynorketamine by Bonaventura et al.

Mol Psychiatry. 2024 Jan;29(1):3-4. doi: 10.1038/s41380-022-01766-6. Epub 2022 Sep 13.

Mouse, rat, and dog bioavailability and mouse oral antidepressant efficacy of ()-hydroxynorketamine.

J Psychopharmacol. 2019 Jan;33(1):12-24. doi: 10.1177/0269881118812095. Epub 2018 Nov 29.

()-hydroxynorketamine exerts mGlu receptor-dependent antidepressant actions.

Proc Natl Acad Sci U S A. 2019 Mar 26;116(13):6441-6450. doi: 10.1073/pnas.1819540116. Epub 2019 Mar 13.

Lack of Antidepressant Effects of (2R,6R)-Hydroxynorketamine in a Rat Learned Helplessness Model: Comparison with (R)-Ketamine.

Int J Neuropsychopharmacol. 2018 Jan 1;21(1):84-88. doi: 10.1093/ijnp/pyx108.

Brain-derived neurotrophic factor in the ventrolateral periaqueductal gray contributes to (2R,6R)-hydroxynorketamine-mediated actions.

Neuropharmacology. 2020 Jun 15;170:108068. doi: 10.1016/j.neuropharm.2020.108068. Epub 2020 Mar 25.

Activity-dependent brain-derived neurotrophic factor signaling is required for the antidepressant actions of (2,6)-hydroxynorketamine.

Proc Natl Acad Sci U S A. 2019 Jan 2;116(1):297-302. doi: 10.1073/pnas.1814709116. Epub 2018 Dec 17.

Antidepressant-relevant concentrations of the ketamine metabolite (2,6)-hydroxynorketamine do not block NMDA receptor function.

Proc Natl Acad Sci U S A. 2019 Mar 12;116(11):5160-5169. doi: 10.1073/pnas.1816071116. Epub 2019 Feb 22.

(R)-Ketamine exerts antidepressant actions partly via conversion to (2R,6R)-hydroxynorketamine, while causing adverse effects at sub-anaesthetic doses.

Br J Pharmacol. 2019 Jul;176(14):2573-2592. doi: 10.1111/bph.14683. Epub 2019 May 13.

(2R,6R)-hydroxynorketamine rescues chronic stress-induced depression-like behavior through its actions in the midbrain periaqueductal gray.

Neuropharmacology. 2018 Sep 1;139:1-12. doi: 10.1016/j.neuropharm.2018.06.033. Epub 2018 Jun 25.

(S)-norketamine and (2S,6S)-hydroxynorketamine exert potent antidepressant-like effects in a chronic corticosterone-induced mouse model of depression.

Pharmacol Biochem Behav. 2020 Apr;191:172876. doi: 10.1016/j.pbb.2020.172876. Epub 2020 Feb 20.

引用本文的文献

Bibliometric insights into astrocytic roles in depression and treatment.

Front Cell Neurosci. 2025 Jan 15;18:1521398. doi: 10.3389/fncel.2024.1521398. eCollection 2024.

Are "mystical experiences" essential for antidepressant actions of ketamine and the classic psychedelics?

Eur Arch Psychiatry Clin Neurosci. 2024 Feb 27. doi: 10.1007/s00406-024-01770-7.

Arketamine for cognitive impairment in psychiatric disorders.

Eur Arch Psychiatry Clin Neurosci. 2023 Oct;273(7):1513-1525. doi: 10.1007/s00406-023-01570-5. Epub 2023 Feb 14.

A Bibliometric Analysis of Research on the Role of BDNF in Depression and Treatment.

Biomolecules. 2022 Oct 12;12(10):1464. doi: 10.3390/biom12101464.

本文引用的文献

The role of hippocampal KCNQ2 channel in antidepressant actions of ketamine.

Neuron. 2022 Jul 20;110(14):2201-2203. doi: 10.1016/j.neuron.2022.05.027.

A systematic review of studies investigating the acute effects of -methyl--aspartate receptor antagonists on behavioural despair in normal animals suggests poor predictive validity.

Brain Neurosci Adv. 2022 Mar 12;6:23982128221081645. doi: 10.1177/23982128221081645. eCollection 2022 Jan-Dec.

Molecular mechanisms underlying the antidepressant actions of arketamine: beyond the NMDA receptor.

Mol Psychiatry. 2022 Jan;27(1):559-573. doi: 10.1038/s41380-021-01121-1. Epub 2021 May 7.

Pharmacological and behavioral divergence of ketamine enantiomers: implications for abuse liability.

Mol Psychiatry. 2021 Nov;26(11):6704-6722. doi: 10.1038/s41380-021-01093-2. Epub 2021 Apr 15.

Ketamine metabolites, clinical response, and gamma power in a randomized, placebo-controlled, crossover trial for treatment-resistant major depression.

Neuropsychopharmacology. 2020 Jul;45(8):1398-1404. doi: 10.1038/s41386-020-0663-6. Epub 2020 Apr 6.

Molecular mechanisms of the rapid-acting and long-lasting antidepressant actions of (R)-ketamine.

Biochem Pharmacol. 2020 Jul;177:113935. doi: 10.1016/j.bcp.2020.113935. Epub 2020 Mar 26.

Intravenous arketamine for treatment-resistant depression: open-label pilot study.

Eur Arch Psychiatry Clin Neurosci. 2021 Apr;271(3):577-582. doi: 10.1007/s00406-020-01110-5. Epub 2020 Feb 20.

Depression researchers rethink popular mouse swim tests.

Nature. 2019 Jul;571(7766):456-457. doi: 10.1038/d41586-019-02133-2.

(2R,6R)-Hydroxynorketamine is not essential for the antidepressant actions of (R)-ketamine in mice.

Neuropsychopharmacology. 2018 Aug;43(9):1900-1907. doi: 10.1038/s41386-018-0084-y. Epub 2018 May 3.

Ketamine has distinct electrophysiological and behavioral effects in depressed and healthy subjects.

Mol Psychiatry. 2019 Jul;24(7):1040-1052. doi: 10.1038/s41380-018-0028-2. Epub 2018 Feb 27.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验